Associations of combined phenotypic aging and genetic risk with incident cancer: A prospective cohort study

  1. Lijun Bian
  2. Zhimin Ma
  3. Xiangjin Fu
  4. Chen Ji
  5. Tianpei Wang
  6. Caiwang Yan
  7. Juncheng Dai
  8. Hongxia Ma
  9. Zhibin Hu
  10. Hongbing Shen  Is a corresponding author
  11. Lu Wang  Is a corresponding author
  12. Meng Zhu  Is a corresponding author
  13. Guangfu Jin  Is a corresponding author
  1. Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, China
  2. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health Nanjing Medical University, China
  3. Department of Chronic Non-Communicable Disease Control, The Affiliated Wuxi Center for Disease Control and Prevention of Nanjing Medical University, Wuxi Center for Disease Control and Prevention, Wuxi Medical Center, Nanjing Medical University, China
  4. Research Units of Cohort Study on Cardiovascular Diseases and Cancers, Chinese Academy of Medical Sciences, China

eLife assessment

This study presents fundamental findings that advance our understanding of the role of phenotypic aging in cancer risk. This article presents compelling results that show Phenotypic Age Acceleration (PhenoAgeAccel) can predict cancer incidence of different types and could be used with genetic risk to facilitate the identification of cancer-susceptible individuals. These results will be of broad interest to the research community and clinicians.

https://doi.org/10.7554/eLife.91101.3.sa0

Abstract

Background:

Age is the most important risk factor for cancer, but aging rates are heterogeneous across individuals. We explored a new measure of aging-Phenotypic Age (PhenoAge)-in the risk prediction of site-specific and overall cancer.

Methods:

Using Cox regression models, we examined the association of Phenotypic Age Acceleration (PhenoAgeAccel) with cancer incidence by genetic risk group among 374,463 participants from the UK Biobank. We generated PhenoAge using chronological age and nine biomarkers, PhenoAgeAccel after subtracting the effect of chronological age by regression residual, and an incidence-weighted overall cancer polygenic risk score (CPRS) based on 20 cancer site-specific polygenic risk scores (PRSs).

Results:

Compared with biologically younger participants, those older had a significantly higher risk of overall cancer, with hazard ratios (HRs) of 1.22 (95% confidence interval, 1.18–1.27) in men, and 1.26 (1.22–1.31) in women, respectively. A joint effect of genetic risk and PhenoAgeAccel was observed on overall cancer risk, with HRs of 2.29 (2.10–2.51) for men and 1.94 (1.78–2.11) for women with high genetic risk and older PhenoAge compared with those with low genetic risk and younger PhenoAge. PhenoAgeAccel was negatively associated with the number of healthy lifestyle factors (Beta = –1.01 in men, p<0.001; Beta = –0.98 in women, p<0.001).

Conclusions:

Within and across genetic risk groups, older PhenoAge was consistently related to an increased risk of incident cancer with adjustment for chronological age and the aging process could be retarded by adherence to a healthy lifestyle.

Funding:

This work was supported by the National Natural Science Foundation of China (82230110, 82125033, 82388102 to GJ; 82273714 to MZ); and the Excellent Youth Foundation of Jiangsu Province (BK20220100 to MZ).

eLife digest

Age is a major risk factor for cancer. Other factors, such as lifestyle or environmental exposures, may increase or mitigate cancer risks. Biological age, which considers accelerated aging processes, may, however, better predict cancer risk than chronological age. Some scientists propose using biological aging measures as an alternative for assessing cancer and other age-related disease risks, as these markers may provide a more accurate assessment of the various factors contributing to cancer risk.

PhenoAge, a measure of biological aging processes in the body, could provide an alternative way to assessing aging-related cancer risks. This tool utilizes an individual’s chronological age and nine biomarkers of aging processes. It has the potential to identify individuals whose aging process is accelerated compared to their peers, potentially indicating an increased cancer risk. This information may empower them to make lifestyle changes that could significantly reduce their risk.

To assess the suitability of PhenoAge, Bian, Ma et al. used nine clinical chemistry biomarkers and chronological age to calculate PhenoAge in 374,463 participants from the UK Biobank. Their findings revealed that people with older PhenoAges – regardless of their genetic risk profiles – have an increased risk of cancer. Individuals with higher PhenoAge scores, indicating accelerated biological aging, had a roughly 25 percent higher risk of developing cancer. Individuals with both a high genetic risk and higher PhenoAge score had roughly double the risk of cancer. People with lower PhenoAges were more likely to have healthier lifestyles. These results suggest that adopting healthier lifestyles may slow the aging process and reduce cancer risk.

While the analyses conducted by Bian, Ma et al. provide promising insights, they also underscore the need for further research. PhenoAge may offer a way to assess biological aging and identify individuals at higher risk of cancer. Those with higher PhenoAge scores may benefit from earlier cancer screening, and adopting a healthier lifestyle could potentially slow down the aging process and reduce their cancer risk. However, more studies in more diverse cohorts of people are needed to confirm that PhenoAge is a reliable marker for cancer risk and to test interventions to slow aging and reduce cancer risks in individuals with accelerated aging.

Introduction

Cancer continues to be the leading cause of death globally and the reduction of cancer-related deaths remains to be a public health priority (Bray et al., 2018). The morbidity and mortality of cancer increase dramatically with age, which demonstrates that aging is the greatest risk factor for cancer (Siegel et al., 2018). Although everyone gets older, individuals are aging at different rates (Rutledge et al., 2022). Therefore, the variation in the pace of aging between person may reflect the differences in susceptibility to cancer and death. Thus, measurement of an individual’s biological age, particularly at the early stage of life, may promote the primary and secondary prevention of cancer through earlier identification of high-risk groups.

Recently, Morgan and colleagues developed and validated a novel multi-system-based aging measurement (Levine et al., 2018), PhenoAge, which has been shown to capture long-term vulnerability to diseases like COVID-19, and strongly predict morbidity and mortality risk in diverse populations (Kuo et al., 2021b; Liu et al., 2018). However, it is largely unknown whether PhenoAge can predict overall cancer risk and identify high-risk individuals for potential personalized prevention.

To date, more than 2000 genetic loci have been identified as susceptibility markers for certain cancers by genome-wide association studies (GWAS) (Buniello et al., 2019). Although the effect of these individual loci is relatively modest on cancer risk, a PRS combining multiple loci together as an indicator of genetic risk has been proved to effectively predict the incidence of site-specific cancer (Dai et al., 2019; Lecarpentier et al., 2017; Mars et al., 2020). Recently, we systematically created site-specific cancer PRS for 20 cancer types, and constructed an incidence-weighted CPRS to assess the effect of genetic risk on overall incident cancer risk based on the UK Biobank (Zhu et al., 2021). Previous studies had indicated an interaction between genetic factors and age on cancer risk (Mavaddat et al., 2015). However, the extent to interaction between genetic factors and PhenoAge on overall cancer risk remained unclear.

In this study, we calculated PhenoAge in accordance with the method described previously and then evaluated the effectiveness of PhenoAge in predicting the risk of overall cancer in the UK Biobank. We also assessed the extent to which a level of accelerated aging was associated with an increased overall cancer risk across groups with a different genetic risk defined by the CPRS.

Methods

Participants

The participants included in this study are derived from the UK Biobank. The UK Biobank is a large population-based cohort study and detail protocol is publicly available (Bycroft et al., 2018). In brief, approximately 500,000 participants aged 40–70 were recruited from 22 assessment centers across England, Scotland, and Wales between 2006 and 2010 at baseline. Each eligible participant completed a written informed consent form and provided information on lifestyle and other potentially health-related aspects through extensive baseline questionnaires, interviews, and physical measurements. Meanwhile, biological samples of participants were also collected for biomarker assays and a blood draw was collected for genotyping. The UK Biobank study has approval from the Multi-center Research Ethics Committee, the National Information Governance Board for Health and Social Care in England and Wales, and the Community Health Index Advisory Group in Scotland (http://www.ukbiobank.ac.uk/ethics/).

PhenoAge and PhenoAgeAccel PRS

We calculated PhenoAge in accordance with the method described previously (Levine et al., 2018). Briefly, PhenoAge was calculated based on mortality scores from the Gompertz proportional hazard model on chronological age and nine multi-system clinical chemistry biomarkers (albumin, creatinine, glucose, [log] C-reactive protein [CRP], lymphocyte percent, mean cell volume, red blood cell distribution width, alkaline phosphatase, and white blood cell count) to predict all-cause mortality. The Biomarkers in the UK Biobank were measured at baseline (2006–2010) for all participants. To correct distribution skewness, we set the top and bottom 1% of values to the 99th and first percentiles. The formula of PhenoAge is given by

PhenoAge=141.50+ln-0.00553×-1.51714×expxb0.00769270.09165

where

xb=-19.907-0.0336×albumin+0.0095×creatinine+0.1953×glucose+0.0954×lnCRP-0.0120×lymphocytepercentage+0.0268×meancorpuscularvolume+0.3306×redbloodcelldistributionwidthRDW+0.00188×alkalinephosphatase+0.0554×whitebloodcellcount+0.0804×age

Finally, we calculated Phenotypic Age Acceleration (PhenoAgeAccel), which was defined as the residual resulting from a linear model when regressing Phenotypic Age on chronological age. Therefore, PhenoAgeAccel represents Phenotypic Age after accounting for chronological age (i.e. whether a person appears older [positive value] or younger [negative value] than expected, biologically, based on his/her age).

55 independent PhenoAgeAccel-associated SNPs (p<5 × 10–8) and corresponding effect sizes were derived from a large-scale PhenoAgeAccel GWAS including 107,460 individuals of European ancestry (Kuo et al., 2021a). A PhenoAgeAccel PRS was created using an additive model as previously described (Dai et al., 2019). In short, the genotype dosage of each risk allele for each individual was summed after multiplying by its respective effect size of PhenoAgeAccel.

PRS calculation and CPRS construction

The calculation of site-specific cancer PRSs and the construction of CPRSs have been described in our previous published study (Zhu et al., 2021). In brief, for individual cancer, risk-associated single nucleotide polymorphisms (SNPs) and corresponding effect sizes were derived from the largest published GWASs in terms of sample size. Next, the dosage of each risk allele for each individual was summed after multiplication with its respective effect size of site-specific cancer. Except for nonmelanoma skin cancer and those without relevant GWAS or significant genetic loci published by now, we derived PRSs for 20 cancer types in this analysis. To generate an indicator of genetic risk for overall cancer, we constructed the CPRS as follows:

CPRSi=k=1KhkPRSi,k

Where CPRSi is the cancer polygenic risk score of ith individual, hk is the age-standardized incidence of site-specific cancer k in the UK population, and PRSi,k is the aforementioned PRS of site-specific cancer k. Given the different spectrum of cancer incidence between men and women, CPRS were constructed for males and females, respectively.

Assessment of healthy lifestyle

We adopted five healthy lifestyle factors according to the World Cancer Research Fund/American Institute of Cancer Research recommendations (https://www.aicr.org/cancer-prevention/) (Shams-White et al., 2019), i.e., no current smoking, no alcohol consumption, regular physical activity, moderate BMI (body-mass index, 18.5~30), and a healthy diet pattern. Participants of no current smoking were defined as never smokers or former smokers who had quit smoking at least 30 years. No alcohol consumption was defined as never alcohol use. Regular physical activity was defined as at least 75 min of vigorous activity per week or 150 min of moderate activity per week (or an equivalent combination) or engaging in vigorous activity once and moderate physical activity at least 5 days a week (Lourida et al., 2019). A healthy diet pattern was ascertained consumption of an increased amount of fruits, vegetables, whole grains, fish, and a reduced amount of red meats and processed meats (Lourida et al., 2019). The lifestyle index ranged from 0 to 5, with a higher index indicating a healthier lifestyle.

Outcomes

Outcomes of incident cancer events in the UK Biobank were ascertained through record electronic linkage with the National Health Service central registers and death registries in England, Wales, and Scotland. Complete follow-up was updated to 31 October 2015 for Scotland, and to 31 March 2016 for England & Wales. Cancer events were coded using the tenth Revision of the International Classification of Diseases. The outcome of all cancer events were obtained from data fields 40006 and 40005 of the UK Biobank.

Statistical analysis

Cancer risk of participants in the UK Biobank was assessed from baseline until to the date of diagnosis, death, loss to follow-up, or date of complete follow-up, whichever occurred first. Multivariable Cox proportional hazards regression analyses were performed to assess associations between PhenoAgeAccel and cancer risk and to estimate hazard ratios (HRs) as well as 95% confidence intervals (CI). Schoenfeld residuals and log-log inspection were used to test the assumption of proportional hazards. HRs associated with per 5 years increased of PhenoAgeAccel was calculated for site-specific cancer and overall cancer, respectively. We compared HRs between biologically younger and older participants. In addition, we calculated HRs for participants at low (the bottom quintile of PhenoAgeAccel), intermediate (quintiles 2–4), and high (the top quintile) accelerated aging, and HRs for participants splitted by decile of accelerated aging.

Meanwhile, participants were also divided into low (the bottom quintile of CPRS), intermediate (quintiles 2–4), and high (the top quintile) genetic risk groups. Absolute risk within each subgroup defined by PhenoAgeAccel and CPRS were calculated as the percentage of incident cancer cases occurring in a given group. We calculated absolute risk increase as the difference in cancer incidences among given groups, extrapolated the difference in 5 year event rates among given groups. The 95% CIs for the absolute risk increase were derived by drawing 1,000 bootstrap samples from the estimation dataset. We performed additive interaction analysis between genetic risk (defined by CPRS) and PhenoAgeAccel on overall cancer risk, as well as genetic risk (defined by PhenoAgeAccel PRS) and lifestyle on PhenoAgeAccel using two indexes: the relative excess risk due to interaction (RERI) and the attributable proportion due to interaction (AP) (Li and Chambless, 2007). The 95% CIs of the RERI and AP were estimated by bootstrap (n=5000), which would contain 0 if there was no additive interaction. We also used multivariable linear regression models to assess associations between the PhenoAgeAccel and individual lifestyle factors with adjustment for age, family history of cancer, Townsend deprivation index, height, and the first 10 principal components of ancestry. All the above-mentioned analyses were performed for men and women separately.

Participants with missing data on any of the covariates were multiple imputed, and independent analyses were also performed based on complete data for sensitivity analyses. Besides, to examine the reliability of our results, we conducted several sensitivity analyses: (1) reclassifying PhenoAgeAccel levels based on quartiles (bottom, 2–3, and top quartiles defined as low, intermediate, and high accelerated aging, respectively) or tertiles (corresponding to low, intermediate, and high accelerated aging) of PhenoAgeAccel; (2) reevaluating the effect of PhenoAgeAccel based on participants of unrelated British ancestry; (3) excluding incident cases of any cancer occurring during the two years of follow-up; and (4) retrained PhenoAge in cancer-free participants based on mortality. All p-values were two-sided and p<0.05 was considered statistically significant. All statistical analyses were performed with R software, version 3.6.3 (R Project for Statistical Computing).

Results

Participants

After removing participants who had withdrawn their consent, had been diagnosed with cancer before baseline, failed to be genotyped, reported a mismatch sex with genetic data, or with missing data on PhenoAge, the final analytic dataset included 374,463 eligible participants (173,431 men and 201,032 women) (Figure 1). Of which, 169,573 participants were biologically older, with 92,189 men, and 77,384 women, whose median PhenoAgeAccel were 3.28 (interquartile range [IQR]: 1.50–6.06) and 3.07 (IQR: 1.33–5.79), respectively; 204,890 participants were biologically younger, with 81,242 men and 123,648 women, whose median PhenoAgeAccel were –2.61 (IQR: –4.35––1.25) and –3.55 (IQR: –5.64––1.81), respectively (Table 1).

Flowchart for filtering participants from the UK Biobank cohort.

Participants who had withdrawn their consent, had been diagnosed with cancer before baseline, failed to be genotyped, reported a mismatch sex with genetic data, or with missing data on Phenotypic Age (PhenoAge) were excluded.

Table 1
Baseline characteristics of participants stratified by Phenotypic Age Acceleration (PhenoAgeAccel) categories.
Men (n=173,431)Women (n=201,032)
Biologically younger
n=81,242
Biologically older
n=92,189
Biologically younger
n=123,648
Biologically older
n=77,384
PhenoAgeAccel, median (IQR), years–2.61 (−4.35–-1.25)3.28 (1.50–6.06)–3.55 (−5.64–-1.81)3.07 (1.33–5.79)
Age at baseline, median (IQR), years57.00 (49.00–62.00)58.00 (50.00–64.00)58.00 (51.00–63.00)56.00 (48.00–62.00)
Height, median (IQR), centimeters176.00 (171.00–181.00)175.00 (171.00–180.00)162.50 (158.00–167.00)162.00 (158.00–166.50)
Townsend deprivation index, median (IQR)–2.34 (−3.76–0.16)–1.86 (−3.52–1.10)–2.33 (−3.73–0.07)–1.79 (−3.44–1.10)
Family history of cancer, n (%)
 No53907 (66.35)60654 (65.79)79800 (64.54)50924 (65.81)
 Yes27335 (33.65)31535 (34.21)43848 (35.46)26460 (34.19)
Healthy lifestyle factors, n (%)
 No current smoking46412 (57.13)43216 (46.88)78743 (63.68)45416 (58.69)
 No alcohol consumption2064 (2.54)2828 (3.07)6221 (5.03)5459 (7.05)
 Normal BMI66120 (81.39)62654 (67.96)103054 (83.34)49003 (63.32)
 Regular physical activity54346 (66.89)57733 (62.62)80629 (65.21)46468 (60.05)
 Healthy diet18540 (22.82)15486 (16.80)39547 (31.98)19826 (25.62)
Healthy lifestyle*, n (%)
 Favorable7781 (9.58)5255 (5.70)17781 (14.38)7178 (9.28)
 Intermediate57683 (71.00)57489 (62.36)87272 (70.58)49324 (63.74)
 Unfavorable15778 (19.42)29445 (31.94)18595 (15.04)20882 (26.98)
Albumin, median (IQR), (g/L)46.20 (44.62–47.85)44.95 (43.28–46.64)45.47 (43.87–47.12)44.04 (42.42–45.70)
Alkaline phosphatase, median (IQR), (U/L)75.00 (64.30–87.40)82.80 (70.10–97.90)78.70 (65.10–93.90)86.20 (70.60–104.00)
Creatinine, median (IQR), (umol/L)77.60 (70.90–84.70)82.50 (74.40–91.60)61.70 (56.00–67.90)65.50 (58.90–73.20)
Glucose, median (IQR), (mmol/l)4.82 (4.49–5.14)5.09 (4.72–5.60)4.84 (4.54–5.14)5.05 (4.70–5.55)
C-reactive protein, median (IQR), (mg/dL)0.09 (0.05–0.16)0.19 (0.10–0.36)0.10 (0.05–0.20)0.25 (0.12–0.51)
Lymphocyte percent, median (IQR), (%)29.86 (25.48–34.48)25.60 (21.22–30.24)31.09 (26.58–35.80)27.00 (22.62–31.61)
Mean cell volume, median (IQR), (fL)90.90 (88.46–93.30)91.90 (89.10–94.74)91.10 (88.60–93.54)90.98 (87.64–94.02)
Red cell distribution width, median (IQR), (%)13.01 (12.70–13.37)13.63 (13.21–14.11)13.10 (12.71–13.50)13.90 (13.40–14.55)
White blood cell count, median (IQR), (1000 cells/uL)6.12 (5.29–7.10)7.27 (6.17–8.51)6.24 (5.37–7.26)7.41 (6.30–8.73)
  1. *

    Healthy lifestyle was defined as favorable (4–5 healthy lifestyle factors), intermediate (2–3 healthy lifestyle factors), and unfavorable (0–1 healthy lifestyle factor).

Associations of PhenoAgeAccel with cancer risk

There were 22,370 incident cancer cases, with 11,532 men and 10,838 women, during a median follow-up of 7.09 years (IQR: 6.35–7.72). The PhenoAgeAccel was significantly associated with increased risk for cancer sites of lip-oral cavity-pharynx, esophagus, stomach, colon-rectum, pancreas, lung, breast, cervix uteri, corpus uteri, prostate, kidney, bladder, multiple myeloma, Hodgkin’s disease, and lymphoid leukemia, while negatively associated with risk of prostate cancer after adjusting for chronological age and other covariates (Figure 2, Supplementary file 1a).

Association results of Phenotypic Age Acceleration (PhenoAgeAccel) with site-specific cancer risk per 5 years increased.

Cox proportional hazards regression adjusted for age, height, cancer family history, Townsend deprivation index at recruitment, and the first 10 principal components of ancestry. Error bars are 95% confidence intervals (CIs).

For overall cancer, we observed an obviously higher distribution of PhenoAgeAccel in incident cancer cases than participants without incident cancer in both men and women (Figure 3A and B). PhenoAgeAccel was significantly associated with an increased risk of overall cancer in men (HR = 1.15, 95% CI, 1.13–1.17, p<0.0001) and women (HR = 1.15, 95% CI, 1.13–1.17, p<0.0001) per 5 years increase (Table 2). We also observed a significant gradient increase in incident cancer risk from decile 1 to decile 10 of PhenoAgeAccel (Figure 3C and D). Compared with biologically younger participants, those older had a significantly higher risk of overall cancer, with HRs of 1.22 (95% CI, 1.18–1.27, p<0.0001) in men, 1.26 (95% CI, 1.22–1.31, p<0.0001) in women, respectively (Figure 3E and F). Besides, Compared with individuals at low accelerated aging (the bottom quintile of PhenoAgeAccel), those in the intermediate (quintiles 2–4) and high accelerated aging (the top quintile) had a significantly higher risk of overall cancer, with HRs of 1.15 (95% CI, 1.09–1.21, p<0.0001) and 1.44 (95% CI, 1.36–1.53, p<0.0001) in men, 1.15 (95% CI, 1.09–1.21, p<0.0001), and 1.46 (95% CI, 1.38–1.55, p<0.0001) in women, respectively. These results did not change after adjustment for genetic risk and lifestyle factors (Table 2). Similar patterns were noted in a series of sensitivity analyses with reclassifying accelerated aging levels according to quartiles or tertiles of the PhenoAgeAccel (Supplementary file 1b), exclusion of incident cancer cases occurred during the two years of follow-up (Supplementary file 1c), in the unimputed data (Supplementary file 1d), in the unrelated British population (Supplementary file 1e), or using retrained PhenoAge in cancer-free participants (Supplementary file 1f).

Effect of Phenotypic Age Acceleration (PhenoAgeAccel) on the risk of incident cancer in the UK Biobank.

The distribution of PhenoAgeAccel between participants with incident cancer and those without incident cancer in the UK Biobank for men(A) and women (B). Participants in the UK Biobank were divided into ten equal groups according to the PhenoAgeAccel for men (C) and women (D), and the hazard ratios (HRs) of each group were compared with those in the bottom decile of PhenoAgeAccel. Error bars are 95% confidence intervals (CIs). Standardized rates of cancer events in younger and older PhenoAge groups in the UK Biobank for men (E) and women (F). HRs and 95% CIs were estimated using Cox proportional hazard models with adjustment for age, height, family history of cancer, Townsend deprivation index, and the first 10 principal components of ancestry. Shaded areas are 95% CIs.

Table 2
Association between Phenotypic Age Acceleration (PhenoAgeAccel) and cancer risk.
Model 1*Model 2
n (cases)Person-YearsHR (95% CI)p valueHR (95% CI)value
MenPer 5 years increase173431 (11532)11906281.15 (1.13–1.17)1.55×10–541.13 (1.11–1.15)5.46×10–44
Category
 Biologically younger81242 (4649)564818Ref.Ref.
 Biologically older92189 (6883)6258101.22 (1.18–1.27)5.31×10–261.19 (1.15–1.24)3.18×10–20
Quintiles
 Low34687 (1864)242519Ref.Ref.
 Intermediate104058 (6668)7163121.15 (1.09–1.21)2.17×10–71.12 (1.07–1.18)8.01×10–6
 High34686 (3000)2317971.44 (1.36–1.53)1.01×10–341.39 (1.31–1.47)1.99×10–27
p for trend3.03×10–371.65×10–29
WomenPer 5 years increase201032 (10838)13935621.15 (1.13–1.17)1.80×10–531.13 (1.11–1.15)1.35×10–41
Category
 Biologically younger123648 (6229)861570Ref.Ref.
 Biologically older77384 (4609)5319931.26 (1.22–1.31)5.91×10–331.23 (1.18–1.28)2.71×10–25
Quintiles
 Low40207 (1946)281912Ref.Ref.
 Intermediate120618 (6351)8363411.15 (1.09–1.21)1.46×10–71.13 (1.07–1.18)5.89×10–6
 High40207 (2541)2753091.46 (1.38–1.55)2.54×10–361.40 (1.32–1.49)5.94×10–28
p for trend4.23×10–371.36×10–28
  1. *

    Cox proportional hazards regression adjusted for Model 1, as well as cancer polygenic risk score and healthy lifestyle.

  2. Defined by quintiles of PhenoAgeAccel: low (the bottom quintile), intermediate (quintiles 2–4), and high (the top quintile).

  3. Cox proportional hazards regression adjusted for age, height, cancer family history, Townsend deprivation index at recruitment, and the first 10 principal components of ancestry.

  4. CI, confidence interval; HR, hazards ratio; Ref, reference.

Joint effect and interaction of genetic factor and PhenoAgeAccel on overall cancer risk

The overall incident cancer risk is associated with both genetic risk and PhenoAgeAccel in a dose-response manner (Figure 4). Of participants with high genetic risk and older PhenoAge, the incidence rates of overall cancer per 100,000 person-years were estimated to be 1477.89 (95% CI, 1410.87–1544.92) in men and 1076.17 (95% CI, 1014.14–1138.19) in women versus 581.06 (95% CI, 537.12–625.00) in men and 594.71 (95% CI, 558.50–630.92) in women with low genetic risk and younger PhenoAge. Approximate double risks [HR, 2.29 (95% CI, 2.10–2.51) in men, p<0.0001; 1.94 (95% CI, 1.78–2.11) in women, p<0.0001] were observed in participants with high genetic risk and older PhenoAge, compared with those with low genetic risk and younger PhenoAge. Similar patterns were noted by reclassifying accelerated aging levels into low (the bottom quintile of PhenoAgeAccel), intermediate (quintiles 2–4), and high (the top quintile) (Figure 4—figure supplement 1). However, we did not observe the interaction between genetic and PhenoAgeAccel on overall cancer risk in men and women (Supplementary file 1g).

Figure 4 with 1 supplement see all
Risk of incident cancer according to genetic and Phenotypic Age Acceleration (PhenoAgeAccel) categories in the UK Biobank for men (A) and women (B).

The hazard ratios (HRs) were estimated using Cox proportional hazard models with adjustment for age, height, family history of cancer, Townsend deprivation index, and the first 10 principal components of ancestry. Participants were divided into younger and older PhenoAge under different genetic risk groups. Error bars are 95% confidence intervals (CIs).

Disadvantages of older PhenoAge with overall incident cancer

In further stratification analyses by genetic risk category with younger PhenoAge as the reference group, we confirmed that older PhenoAge was significantly associated with a higher incident cancer risk across genetic risk groups (Table 3). Among participants at high genetic risk, the standardized 5 year incident cancer rates were 5.78% and 4.58% for biologically younger men and women versus 6.90% and 5.17% for those older, respectively. Similarly, among participants at low genetic risk, the standardized 5 year incident cancer rates increased from 2.71% and 2.83% for biologically younger to 3.87% and 3.39% for those older in men and women, respectively. Similar patterns were noted by reclassifying accelerated aging levels into low (the bottom quintile of PhenoAgeAccel), intermediate (quintiles 2–4), and high (the top quintile) (Supplementary file 1h).

Table 3
Risk of incident cancer according to Phenotypic Age Acceleration (PhenoAgeAccel) categories within each genetic risk level*.
GenderPhenoAgeAccel categoryLow genetic riskIntermediate genetic riskHigh genetic risk
Biologically youngerBiologically olderBiologically youngerBiologically olderBiologically youngerBiologically older
MenNo. of cases/Person years668/1149621031/1245262606/3389504012/3767821375/1109071840/124502
Hazards ratioRef.1.29
(1.17–1.42)
Ref.1.27
(1.21–1.33)
Ref.1.10
(1.02–1.18)
(95% CI)
p value3.53×10–73.15×10–211.07×10–2
Absolute risk (%)-
5 years (95% CI)
2.71
(2.49–2.94)
3.87
(3.60–4.14)
3.57
(3.41–3.72)
4.95
(4.78–5.13)
5.78
(5.44–6.11)
6.90
(6.55–7.26)
Absolute risk increase (%)-
5 years (95% CI)
Ref.1.16
(0.84–1.46)
Ref.1.39
(1.19–1.60)
Ref.1.13
(0.68–1.52)
WomenNo. of cases/Person years1030/173195761/1069373579/5186112704/3187531620/1697641144/106303
Hazards ratioRef.1.25
(1.14–1.38)
Ref.1.30
(1.24–1.37)
Ref.1.19
(1.10–1.28)
(95% CI)
p value2.65×10–61.84×10–248.19×10–6
Absolute risk (%) -
5 years (95% CI)
2.83
(2.63–3.02)
3.39
(3.12–3.65)
3.27
(3.15–3.39)
4.02
(3.86–4.19)
4.58
(4.33–4.83)
5.17
(4.84–5.49)
Absolute risk increase (%)-
5 years (95% CI)
Ref.0.56
(0.26–0.86)
Ref.0.76
(0.57–0.93)
Ref.0.59
(0.23–0.98)
  1. *

    Cox proportional hazards regression is adjusted for age, height, family history of cancer, Townsend deprivation index, height, and the first 10 principal components of ancestry.

  2. CI, confidence interval; Ref, reference.

In addition, to evaluate the implication for cancer screening in populations with different PhenoAgeAccel, we estimated the 5 year absolute risk of overall cancer between biologically younger and older participants with increasing age. Assuming 2% of absolute risk within the next 5 years as the threshold to be recommended for cancer screening, biologically younger men would reach the threshold at age 52, whereas those older men would reach the threshold at age 50; similarly, biologically younger women would reach the 2% of 5 year absolute risk at age 46, whereas those older women would reach the threshold at age 44 (Figure 5).

Absolute risk estimates of overall cancer based on the UK Biobank for men (A) and women (B).

The x-axis is chronological age. The curves describe the average risk of participants in younger and older Phenotypic Age (PhenoAge) groups. The dashed curve represents the average risk of the whole population at different ages. The red horizontal dotted line represents 2% of 5 year absolute risks of overall cancer.

Associations of lifestyle factors with PhenoAgeAccel

In the UK Biobank, biologically younger men (9.6%, 7781/81,242) and women (14.4%, 17,781/123,648) were more likely to have a favorable lifestyle (4–5 healthy lifestyle factors) than older men (5.7%, 5255/92,189) and women (9.3%, 7178/77,384) (Table 1). Among both men and women, we observed that PhenoAgeAccel decreased with the increase of healthy lifestyle factors (Supplementary file 1i). In addition, we found a significant negative correlation between the number of healthy lifestyle factors and PhenoAgeAccel (Beta = –1.01 in men, p<0.001; Beta = –0.98 in women, p<0.001) (Supplementary file 1j). However, we did not observe any interaction between genetic risk and lifestyle on PhenoAgeAccel in both men and women (Supplementary file 1k).

Discussion

In this study, we calculated PhenoAgeAccel to explore the effect of accelerated aging on the risk of cancer, and demonstrated a positive association between accelerated aging and increased cancer risk after adjustment for chronological age in the UK Biobank. Meanwhile, older PhenoAge was consistently associated with an increased absolute risk of incident cancer within each genetic risk group; and participants with high genetic risk and older PhenoAge had the greatest incident cancer risk. Therefore, our findings provided the evidence for PhenoAgeAccel to be used for risk stratification of cancer, which were independent from genetic risk. Moreover, we also demonstrated that participants with older biological age often reaches the screening threshold 2 years in advance compared with biologically younger peers; and keeping a healthy lifestyle can effectively slow down the aging process.

Older age has been long recognized as the main risk factor for cancer, and the multistage model of carcinogenesis posits that the exponential increase in cancer incidence with age were mainly resulted from the sequential accumulation of oncogenic mutations in different tissues throughout life (Laconi et al., 2020). In consistent with this, age and exposure (i.e. smoking, ultraviolet light) dependent mutation signatures have been identified in several cancers by tissue sequencing (Alexandrov et al., 2020). However, biological aging is an enormously complex process and is thought to be influenced by multiple genetic and environmental factors (van Dongen et al., 2016). Therefore, several biomarkers, i.e., ‘aging clocks’ derived from epigenomic, transcriptomic, proteomic, and metabolomic data, have been proposed to measure the biological age and predict the risk of cancer and other diseases (Rutledge et al., 2022; Zhang et al., 2022). However, these measures were usually based on omics data and was not suitable for application in large populations by now. As a result, results from this study would provide a cost-effective indicator for measuring biological age as well as a novel biomarker for cancer risk prediction.

The associations between biological age and cancer risk has been investigated by several studies recently (Li et al., 2022) explored three DNA methylation phenotypic age and cancer risk in four subsets of a population-based cohort from Germany, and reported strong positive associations for lung cancer, while strong inverse associations for breast cancer (Li et al., 2022). Meanwhile, results from the Melbourne Collaborative Cohort Study reported that epigenetic aging was associated with increased cancer risk of kidney cancer and B-cell lymphoma (Dugué et al., 2018). However, because of sample size, the association results were still inconsistent for DNA methylation phenotypic age among different studies. Leukocyte telomere length was also significantly associated with age and were regarded as an indicator of aging. Based on data from the UK Biobank, (Schneider et al., 2022) recently explored the associations between telomere length and risk of several diseases, and reported significant positive associations of telomere length for lymphoid leukemia, multiple myeloma, non-Hodgkin lymphoma, esophagus cancer, while negative associations for malignant neoplasm of brain, mesothelioma, and melanoma (Schneider et al., 2022). The positive associations were in consistent with our findings, however, the negative associations were not significant in our study. Meanwhile, the study did not indicate associations for other cancers, including cancers of lung, stomach, pancreas, and kidney, which showed relatively large effects (HR >1.3) in our study. These findings indicated that the different measures of biological age may reflect the different aspects of aging, and could be joint application in cancer risk assessment.

Recently, several studies have confirmed the associations between PhenoAgeAccel and cancer risk. Mak et al., 2023 explored three measures of biological age, including PhenoAge, and assessed their associations with the incidence of overall cancer and five common cancers (breast, prostate, lung, colorectal, and melanoma). In our previous study, we investigated the association between PhenoAgeAccel and lung cancer risk and analyzed the joint and interactive effects of PhenoAgeAccel and genetic factors on the risk of lung cancer (Ma et al., 2023). In comparison to these studies, our analysis expanded the range of cancers to 20 types and further explored the associations in different genetic and lifestyle contexts. Moreover, we also evaluated the potential implications of PhenoAge in population-level cancer screening. In addition, we observed a negative association between PhenoAgeAccel and prostate cancer risk. The unexpected association may have been confounded by diabetes and altered glucose metabolism, both of which are closely linked to aging. When we removed HbA1c and serum glucose from the biological age algorithms, the association became non-statistically significant. Similar findings were also reported by Mak et al., 2023 and Dugué et al., 2021.

The associations between PhenoAgeAccel and increased cancer risk may be partly attribute to a result of decline in the immune system and accumulation of environmental carcinogenic factors. Recent GWASs of PhenoAgeAccel showed that SNPs associated with PhenoAgeAccel were enriched in pathways of immune system and activation of pro-inflammatory (Kuo et al., 2021a; Levine et al., 2018). In addition to genetics, behaviors (i.e. obesity, smoking, alcohol consumption, and physical activity), and life course circumstances (i.e. socioenvironmental circumstances during childhood and adulthood) were reported to account for about 30% variances of phenotypic aging (Liu et al., 2019). This was in accordance with our findings that, adherence to healthy lifestyles (involving no current smoking, normal BMI, regular physical activity, and healthy diet) could slow down the aging process. In other words, these healthy lifestyles considered in our and previous studies may be causal drivers of phenotypic aging, they represent a more targetable strategy for reducing overall cancer burden by retarding the aging process. Therefore, PhenoAge provides a meaningful intermediate phenotype that can be used to guide interventions for high-risk groups and track intervention efficacy (Liu et al., 2019).

This study has several strengths, including a large sample size, a prospective design of the UK Biobank study, and an effective application of PhenoAgeAccel in predicting the risk of overall cancer. Nevertheless, we also acknowledge several limitations. First, we calculated PhenoAge based on 9 biomarkers from blood, which were measured at baseline. As such, we were unable to access the change of PhenoAgeAccel during the follow-up period. Second, previous studies have indicated that patricians in the UK Biobank differ from the general UK population because of low participation and healthy volunteer bias (Fry et al., 2017). Finally, even though the findings were achieved from participants with diverse ethnic backgrounds of the UK Biobank, the generalizability of our findings should be further assessed in more diverse populations when available.

In summary, our study showed that accelerated aging, which was measured by PhenoAgeAccel, was consistently related to an increased risk of several site-specific cancer and overall cancer with adjustment for chronological age, within and across genetic risk groups. PhenoAgeAccel can serve as a productive tool to facilitate the identification of cancer susceptible individuals, in combination with individual’s genetic background, and act as an intermediate phenotype to guide interventions for high-risk groups and track intervention efficacy.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. The data underlying the results presented in the study are available from the UK Biobank (https://www.ukbiobank.ac.uk; Application Number: 60169).

References

    1. Lecarpentier J
    2. Silvestri V
    3. Kuchenbaecker KB
    4. Barrowdale D
    5. Dennis J
    6. McGuffog L
    7. Soucy P
    8. Leslie G
    9. Rizzolo P
    10. Navazio AS
    11. Valentini V
    12. Zelli V
    13. Lee A
    14. Amin Al Olama A
    15. Tyrer JP
    16. Southey M
    17. John EM
    18. Conner TA
    19. Goldgar DE
    20. Buys SS
    21. Janavicius R
    22. Steele L
    23. Ding YC
    24. Neuhausen SL
    25. Hansen TVO
    26. Osorio A
    27. Weitzel JN
    28. Toss A
    29. Medici V
    30. Cortesi L
    31. Zanna I
    32. Palli D
    33. Radice P
    34. Manoukian S
    35. Peissel B
    36. Azzollini J
    37. Viel A
    38. Cini G
    39. Damante G
    40. Tommasi S
    41. Peterlongo P
    42. Fostira F
    43. Hamann U
    44. Evans DG
    45. Henderson A
    46. Brewer C
    47. Eccles D
    48. Cook J
    49. Ong KR
    50. Walker L
    51. Side LE
    52. Porteous ME
    53. Davidson R
    54. Hodgson S
    55. Frost D
    56. Adlard J
    57. Izatt L
    58. Eeles R
    59. Ellis S
    60. Tischkowitz M
    61. EMBRACE
    62. Godwin AK
    63. Meindl A
    64. Gehrig A
    65. Dworniczak B
    66. Sutter C
    67. Engel C
    68. Niederacher D
    69. Steinemann D
    70. Hahnen E
    71. Hauke J
    72. Rhiem K
    73. Kast K
    74. Arnold N
    75. Ditsch N
    76. Wang-Gohrke S
    77. Wappenschmidt B
    78. Wand D
    79. Lasset C
    80. Stoppa-Lyonnet D
    81. Belotti M
    82. Damiola F
    83. Barjhoux L
    84. Mazoyer S
    85. GEMO Study Collaborators
    86. Van Heetvelde M
    87. Poppe B
    88. De Leeneer K
    89. Claes KBM
    90. de la Hoya M
    91. Garcia-Barberan V
    92. Caldes T
    93. Perez Segura P
    94. Kiiski JI
    95. Aittomäki K
    96. Khan S
    97. Nevanlinna H
    98. van Asperen CJ
    99. HEBON
    100. Vaszko T
    101. Kasler M
    102. Olah E
    103. Balmaña J
    104. Gutiérrez-Enríquez S
    105. Diez O
    106. Teulé A
    107. Izquierdo A
    108. Darder E
    109. Brunet J
    110. Del Valle J
    111. Feliubadalo L
    112. Pujana MA
    113. Lazaro C
    114. Arason A
    115. Agnarsson BA
    116. Johannsson OT
    117. Barkardottir RB
    118. Alducci E
    119. Tognazzo S
    120. Montagna M
    121. Teixeira MR
    122. Pinto P
    123. Spurdle AB
    124. Holland H
    125. KConFab Investigators
    126. Lee JW
    127. Lee MH
    128. Lee J
    129. Kim SW
    130. Kang E
    131. Kim Z
    132. Sharma P
    133. Rebbeck TR
    134. Vijai J
    135. Robson M
    136. Lincoln A
    137. Musinsky J
    138. Gaddam P
    139. Tan YY
    140. Berger A
    141. Singer CF
    142. Loud JT
    143. Greene MH
    144. Mulligan AM
    145. Glendon G
    146. Andrulis IL
    147. Toland AE
    148. Senter L
    149. Bojesen A
    150. Nielsen HR
    151. Skytte AB
    152. Sunde L
    153. Jensen UB
    154. Pedersen IS
    155. Krogh L
    156. Kruse TA
    157. Caligo MA
    158. Yoon SY
    159. Teo SH
    160. von Wachenfeldt A
    161. Huo D
    162. Nielsen SM
    163. Olopade OI
    164. Nathanson KL
    165. Domchek SM
    166. Lorenchick C
    167. Jankowitz RC
    168. Campbell I
    169. James P
    170. Mitchell G
    171. Orr N
    172. Park SK
    173. Thomassen M
    174. Offit K
    175. Couch FJ
    176. Simard J
    177. Easton DF
    178. Chenevix-Trench G
    179. Schmutzler RK
    180. Antoniou AC
    181. Ottini L
    (2017) Prediction of breast and prostate cancer risks in male brca1 and brca2 mutation carriers using polygenic risk scores
    Journal of Clinical Oncology 35:2240–2250.
    https://doi.org/10.1200/JCO.2016.69.4935
    1. Mavaddat N
    2. Pharoah PDP
    3. Michailidou K
    4. Tyrer J
    5. Brook MN
    6. Bolla MK
    7. Wang Q
    8. Dennis J
    9. Dunning AM
    10. Shah M
    11. Luben R
    12. Brown J
    13. Bojesen SE
    14. Nordestgaard BG
    15. Nielsen SF
    16. Flyger H
    17. Czene K
    18. Darabi H
    19. Eriksson M
    20. Peto J
    21. Dos-Santos-Silva I
    22. Dudbridge F
    23. Johnson N
    24. Schmidt MK
    25. Broeks A
    26. Verhoef S
    27. Rutgers EJ
    28. Swerdlow A
    29. Ashworth A
    30. Orr N
    31. Schoemaker MJ
    32. Figueroa J
    33. Chanock SJ
    34. Brinton L
    35. Lissowska J
    36. Couch FJ
    37. Olson JE
    38. Vachon C
    39. Pankratz VS
    40. Lambrechts D
    41. Wildiers H
    42. Van Ongeval C
    43. van Limbergen E
    44. Kristensen V
    45. Grenaker Alnæs G
    46. Nord S
    47. Borresen-Dale AL
    48. Nevanlinna H
    49. Muranen TA
    50. Aittomäki K
    51. Blomqvist C
    52. Chang-Claude J
    53. Rudolph A
    54. Seibold P
    55. Flesch-Janys D
    56. Fasching PA
    57. Haeberle L
    58. Ekici AB
    59. Beckmann MW
    60. Burwinkel B
    61. Marme F
    62. Schneeweiss A
    63. Sohn C
    64. Trentham-Dietz A
    65. Newcomb P
    66. Titus L
    67. Egan KM
    68. Hunter DJ
    69. Lindstrom S
    70. Tamimi RM
    71. Kraft P
    72. Rahman N
    73. Turnbull C
    74. Renwick A
    75. Seal S
    76. Li J
    77. Liu J
    78. Humphreys K
    79. Benitez J
    80. Pilar Zamora M
    81. Arias Perez JI
    82. Menéndez P
    83. Jakubowska A
    84. Lubinski J
    85. Jaworska-Bieniek K
    86. Durda K
    87. Bogdanova NV
    88. Antonenkova NN
    89. Dörk T
    90. Anton-Culver H
    91. Neuhausen SL
    92. Ziogas A
    93. Bernstein L
    94. Devilee P
    95. Tollenaar R
    96. Seynaeve C
    97. van Asperen CJ
    98. Cox A
    99. Cross SS
    100. Reed MWR
    101. Khusnutdinova E
    102. Bermisheva M
    103. Prokofyeva D
    104. Takhirova Z
    105. Meindl A
    106. Schmutzler RK
    107. Sutter C
    108. Yang R
    109. Schürmann P
    110. Bremer M
    111. Christiansen H
    112. Park-Simon TW
    113. Hillemanns P
    114. Guénel P
    115. Truong T
    116. Menegaux F
    117. Sanchez M
    118. Radice P
    119. Peterlongo P
    120. Manoukian S
    121. Pensotti V
    122. Hopper JL
    123. Tsimiklis H
    124. Apicella C
    125. Southey MC
    126. Brauch H
    127. Brüning T
    128. Ko YD
    129. Sigurdson AJ
    130. Doody MM
    131. Hamann U
    132. Torres D
    133. Ulmer HU
    134. Försti A
    135. Sawyer EJ
    136. Tomlinson I
    137. Kerin MJ
    138. Miller N
    139. Andrulis IL
    140. Knight JA
    141. Glendon G
    142. Marie Mulligan A
    143. Chenevix-Trench G
    144. Balleine R
    145. Giles GG
    146. Milne RL
    147. McLean C
    148. Lindblom A
    149. Margolin S
    150. Haiman CA
    151. Henderson BE
    152. Schumacher F
    153. Le Marchand L
    154. Eilber U
    155. Wang-Gohrke S
    156. Hooning MJ
    157. Hollestelle A
    158. van den Ouweland AMW
    159. Koppert LB
    160. Carpenter J
    161. Clarke C
    162. Scott R
    163. Mannermaa A
    164. Kataja V
    165. Kosma VM
    166. Hartikainen JM
    167. Brenner H
    168. Arndt V
    169. Stegmaier C
    170. Karina Dieffenbach A
    171. Winqvist R
    172. Pylkäs K
    173. Jukkola-Vuorinen A
    174. Grip M
    175. Offit K
    176. Vijai J
    177. Robson M
    178. Rau-Murthy R
    179. Dwek M
    180. Swann R
    181. Annie Perkins K
    182. Goldberg MS
    183. Labrèche F
    184. Dumont M
    185. Eccles DM
    186. Tapper WJ
    187. Rafiq S
    188. John EM
    189. Whittemore AS
    190. Slager S
    191. Yannoukakos D
    192. Toland AE
    193. Yao S
    194. Zheng W
    195. Halverson SL
    196. González-Neira A
    197. Pita G
    198. Rosario Alonso M
    199. Álvarez N
    200. Herrero D
    201. Tessier DC
    202. Vincent D
    203. Bacot F
    204. Luccarini C
    205. Baynes C
    206. Ahmed S
    207. Maranian M
    208. Healey CS
    209. Simard J
    210. Hall P
    211. Easton DF
    212. Garcia-Closas M
    (2015) Prediction of breast cancer risk based on profiling with common genetic variants
    Journal of the National Cancer Institute 107:djv036.
    https://doi.org/10.1093/jnci/djv036

Article and author information

Author details

  1. Lijun Bian

    1. Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
    2. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health Nanjing Medical University, Nanjing, China
    Contribution
    Data curation, Formal analysis, Validation, Visualization, Writing – original draft, Writing – review and editing
    Contributed equally with
    Zhimin Ma
    Competing interests
    No competing interests declared
  2. Zhimin Ma

    Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
    Contribution
    Data curation, Formal analysis, Validation, Visualization, Writing – review and editing
    Contributed equally with
    Lijun Bian
    Competing interests
    No competing interests declared
  3. Xiangjin Fu

    Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
    Contribution
    Data curation, Validation, Visualization, Writing – review and editing
    Competing interests
    No competing interests declared
  4. Chen Ji

    Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
    Contribution
    Data curation, Validation, Visualization
    Competing interests
    No competing interests declared
  5. Tianpei Wang

    Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
    Contribution
    Formal analysis, Validation, Visualization, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared
  6. Caiwang Yan

    1. Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
    2. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health Nanjing Medical University, Nanjing, China
    3. Department of Chronic Non-Communicable Disease Control, The Affiliated Wuxi Center for Disease Control and Prevention of Nanjing Medical University, Wuxi Center for Disease Control and Prevention, Wuxi Medical Center, Nanjing Medical University, Wuxi, China
    Contribution
    Methodology, Writing – review and editing
    Competing interests
    No competing interests declared
  7. Juncheng Dai

    1. Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
    2. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health Nanjing Medical University, Nanjing, China
    Contribution
    Methodology, Writing – review and editing
    Competing interests
    No competing interests declared
  8. Hongxia Ma

    1. Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
    2. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health Nanjing Medical University, Nanjing, China
    Contribution
    Supervision, Project administration, Writing – review and editing
    Competing interests
    No competing interests declared
  9. Zhibin Hu

    1. Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
    2. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health Nanjing Medical University, Nanjing, China
    Contribution
    Conceptualization, Supervision, Project administration, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8277-5234
  10. Hongbing Shen

    1. Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
    2. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health Nanjing Medical University, Nanjing, China
    3. Research Units of Cohort Study on Cardiovascular Diseases and Cancers, Chinese Academy of Medical Sciences, Beijing, China
    Contribution
    Conceptualization, Resources, Supervision, Project administration, Writing – review and editing
    For correspondence
    hbshen@njmu.edu.cn
    Competing interests
    No competing interests declared
  11. Lu Wang

    Department of Chronic Non-Communicable Disease Control, The Affiliated Wuxi Center for Disease Control and Prevention of Nanjing Medical University, Wuxi Center for Disease Control and Prevention, Wuxi Medical Center, Nanjing Medical University, Wuxi, China
    Contribution
    Conceptualization, Formal analysis, Supervision, Validation, Writing – review and editing
    For correspondence
    wanglu123@njmu.edu.cn
    Competing interests
    No competing interests declared
  12. Meng Zhu

    1. Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
    2. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health Nanjing Medical University, Nanjing, China
    3. Department of Chronic Non-Communicable Disease Control, The Affiliated Wuxi Center for Disease Control and Prevention of Nanjing Medical University, Wuxi Center for Disease Control and Prevention, Wuxi Medical Center, Nanjing Medical University, Wuxi, China
    Contribution
    Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Writing – original draft, Writing – review and editing
    For correspondence
    zhmnjmu@njmu.edu.cn
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5122-1733
  13. Guangfu Jin

    1. Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
    2. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine and China International Cooperation Center for Environment and Human Health Nanjing Medical University, Nanjing, China
    3. Department of Chronic Non-Communicable Disease Control, The Affiliated Wuxi Center for Disease Control and Prevention of Nanjing Medical University, Wuxi Center for Disease Control and Prevention, Wuxi Medical Center, Nanjing Medical University, Wuxi, China
    Contribution
    Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Writing – review and editing
    For correspondence
    guangfujin@njmu.edu.cn
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0249-5337

Funding

National Natural Science Foundation of China (82230110)

  • Guangfu Jin

National Natural Science Foundation of China (82125033)

  • Guangfu Jin

National Natural Science Foundation of China (82388102)

  • Guangfu Jin

National Natural Science Foundation of China (82273714)

  • Meng Zhu

Excellent Youth Foundation of Jiangsu Province (BK20220100)

  • Meng Zhu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

The authors thank the investigators and participants in UK Biobank for their contributions to this study. This work was supported by the National Natural Science Foundation of China (82230110, 82125033, 82388102 to GJ; 82273714 to MZ); and the Excellent Youth Foundation of Jiangsu Province (BK20220100 to MZ).

Ethics

UK Biobank has received ethics approval from the Research Ethics Committee (ref. 11/NW/0382).

Version history

  1. Sent for peer review:
  2. Preprint posted:
  3. Reviewed Preprint version 1:
  4. Reviewed Preprint version 2:
  5. Version of Record published:

Cite all versions

You can cite all versions using the DOI https://doi.org/10.7554/eLife.91101. This DOI represents all versions, and will always resolve to the latest one.

Copyright

© 2024, Bian, Ma et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,223
    views
  • 101
    downloads
  • 2
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Lijun Bian
  2. Zhimin Ma
  3. Xiangjin Fu
  4. Chen Ji
  5. Tianpei Wang
  6. Caiwang Yan
  7. Juncheng Dai
  8. Hongxia Ma
  9. Zhibin Hu
  10. Hongbing Shen
  11. Lu Wang
  12. Meng Zhu
  13. Guangfu Jin
(2024)
Associations of combined phenotypic aging and genetic risk with incident cancer: A prospective cohort study
eLife 13:RP91101.
https://doi.org/10.7554/eLife.91101.3

Share this article

https://doi.org/10.7554/eLife.91101

Further reading

    1. Cancer Biology
    2. Immunology and Inflammation
    Simei Go, Constantinos Demetriou ... Eric O Neill
    Research Article

    The immunosuppressive microenvironment in pancreatic ductal adenocarcinoma (PDAC) prevents tumor control and strategies to restore anti-cancer immunity (i.e. by increasing CD8 T-cell activity) have had limited success. Here, we demonstrate how inducing localized physical damage using ionizing radiation (IR) unmasks the benefit of immunotherapy by increasing tissue-resident natural killer (trNK) cells that support CD8 T activity. Our data confirms that targeting mouse orthotopic PDAC tumors with IR together with CCR5 inhibition and PD1 blockade reduces E-cadherin positive tumor cells by recruiting a hypoactive NKG2D-ve NK population, phenotypically reminiscent of trNK cells, that supports CD8 T-cell involvement. We show an equivalent population in human single-cell RNA sequencing (scRNA-seq) PDAC cohorts that represents immunomodulatory trNK cells that could similarly support CD8 T-cell levels in a cDC1-dependent manner. Importantly, a trNK signature associates with survival in PDAC and other solid malignancies revealing a potential beneficial role for trNK in improving adaptive anti-tumor responses and supporting CCR5 inhibitor (CCR5i)/αPD1 and IR-induced damage as a novel therapeutic approach.

    1. Cancer Biology
    Hyungtai Sim, Hyun Jung Park ... Murim Choi
    Research Article

    Clonal hematopoiesis of indeterminate potential (CHIP) allows estimation of clonal dynamics and documentation of somatic mutations in the hematopoietic system. Recent studies utilizing large cohorts of the general population and patients have revealed significant associations of CHIP burden with age and disease status, including in cancer and chronic diseases. An increasing number of cancer patients are treated with immune checkpoint inhibitors (ICIs), but the association of ICI response in non-small cell lung cancer (NSCLC) patients with CHIP burden remains to be determined. We collected blood samples from 100 metastatic NSCLC patients before and after ICI for high-depth sequencing of the CHIP panel and 63 samples for blood single-cell RNA sequencing. Whole exome sequencing was performed in an independent replication cohort of 180 patients. The impact of CHIP status on the immunotherapy response was not significant. However, metastatic lung cancer patients showed higher CHIP prevalence (44/100 for patients vs. 5/42 for controls; p = 0.01). In addition, lung squamous cell carcinoma (LUSC) patients showed increased burden of larger clones compared to lung adenocarcinoma (LUAD) patients (8/43 for LUSC vs. 2/50 for LUAD; p = 0.04). Furthermore, single-cell RNA-seq analysis of the matched patients showed significant enrichment of inflammatory pathways mediated by NF-κB in myeloid clusters of the severe CHIP group. Our findings suggest minimal involvement of CHIP mutation and clonal dynamics during immunotherapy but a possible role of CHIP as an indicator of immunologic response in NSCLC patients.